Current status of never functional imaging in evaluating the diagnosis and therapeutic effect of Parkinson disease

Chinese Journal of Clinical Rehabilitation

Volumn 10, Issue 14, 2006, Pages 135-137

  Wang, Yu Huan ^a   Zhao, Chang Jiu ^a   Yang, Zhi Jie ^a   Fu, Peng ^a   Zhang, Rui ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBON 11; DOPA; DOPAMINE RECEPTOR; FLUORODEOXYGLUCOSE F 18; RACLOPRIDE C 11;

ARTICLE; CELL SURVIVAL; CHINESE; COMPUTER SYSTEM; CORRELATION ANALYSIS; DATA BASE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; LONGITUDINAL STUDY; MEDLINE; NERVE FUNCTION; NERVE TRANSPLANTATION; NEUROLOGIC DISEASE; NONHUMAN; ONLINE ANALYSIS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; PUBLISHING; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 33747290741     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Ishikawa T,Dhawan V,Kazumata K,et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37(11):1760-5
2. Brooks DJ, Salmon EP, Mathias CJ,et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.Brain 1990;113(Pt 5):1539-52
3. Eidelberg D, Moeller JR, Ishikawa T,et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45(11):1995-2004
4. Przedborski S, Giladi N,Takikawa S,et al.Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome.Neurology 1994;44(9):1622-8
5. Bhatt MH,Snow BJ, Martin WR, et al. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.Ann Neurol 1991;29(6):673-7
6. Vingerhoets FJ, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.Ann Neurol 1994;36(5):759-64
7. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.Brain 1996;119 (Pt 2):585-91
8. Remy P, Samson Y,Hantraye P, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease.Arch Neurol 2002;59(4):580-6
9. Sawle GV, Bloomfield PM, Bjorklund A, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.Ann Neurol 1992;31(2).166-73
10. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease.Arch Neurol 1999;56(2):179-87
11. Antonini A, Leenders KL,Reist H, et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride.Arch Neurol 1093;50(5):474-80
12. Antoninini A, Schwarz J, Oertel WH, et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44(7):1325-9
13. Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.Mov Disord 1997;12(1):33-8
14. Rinne JO, Laihinen A, Nagren K, et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.J Neurosci Res 1990;27(4):494-9
15. Shinotoh H, Inoue O,Hirayama k, et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.J Neurol Neurosurg Psychiatry 1993;56(5):467-72
16. Antonini A, Kazumata K, Feigin A,et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET.Mov Disord 1998;13(2):268-74
17. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism.J Cereb Blood Flow Metab 1994;14(5):783-801
18. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.Mov Disord 1990;5(3):203-13
19. Eidelberg D, Moeller JR, Ishikawa T, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease.Ann Neurol 1996;39(4):450-9
20. Knudsen GM,Karlsborg M,Thomsen G,et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.Eur J Nucl Med Mol Imaging 2004;31(12):1631-8